Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: A randomized trial

JAMA

Volumn 306, Issue 5, 2011, Pages 493-502

  Krystal, John H ^a,b,c,d   Rosenheck, Robert A ^b,c,e   Cramer, Joyce A ^b,c   Vessicchio, Jennifer C ^b,c   Jones, Karen M ^f   Vertrees, Julia E ^g   Horney, Rebecca A ^f   Huang, Grant D ^h   Stock, Christopher ⁱ  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE NEW HAVEN HOSPITAL   (United States)

^e VA New England Mental Illness and Clinical Center (MIRECC)   (United States)

^f VA Cooperative Studies Program Coordinating Center   (United States)

^g University of New Mexico   (United States)

^h Office of Research and Development   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICIAL ADMINISTERED POST TRAUMATIC STRESS DISORDER SCALE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HAMILTON ANXIETY SCALE; HUMAN; HYPERSALIVATION; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT COMPLIANCE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SHORT FORM 36; SIDE EFFECT; SOLDIER; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; VETERAN; WEIGHT GAIN;

EID: 79961040968     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1080     Document Type: Article

References (47)

1. Kulka RA, Schlenger WE, Fairbank J. Trauma and the Vietnam War Generation. New York, NY: Bruner- Mazel; 1990.
2. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med. 2004;351(1):13-22. (Pubitemid 38857243)
3. Thomas JL, Wilk JE, Riviere LA, McGurk D, Castro CA, Hoge CW. Prevalence of mental health problems and functional impairment among active component and National Guard soldiers 3 and 12 months following combat in Iraq. Arch Gen Psychiatry. 2010;67(6):614-623.
4. Brady K, Pearlstein T, Asnis GM, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder. JAMA. 2000;283(14):1837-1844. (Pubitemid 30207620)
5. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry. 2001;58(5):485-492. (Pubitemid 32411330)
6. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD. Am J Psychiatry. 2001;158(12):1982-1988.
7. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD. Paroxetine in the treatment of chronic posttraumatic stress disorder. J Clin Psychiatry. 2001;62(11):860-868.
8. Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the US Department of Veterans Affairs. J Clin Psychiatry. 2008;69(6):959-965.
9. Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JR. Lack of efficacy for fluoxetine in PTSD. Ann Clin Psychiatry. 2000;12(2):101-105.
10. van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry. 1994;55(12):517-522.
11. Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry. 2007;68(5):711-720. (Pubitemid 46841854)
12. Berger W, Mendlowicz MV, Marques-Portella C, et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):169-180.
13. Pae CU, Lim HK, Peindl K, et al. The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder. Int Clin Psychopharmacol. 2008;23(1):1-8.
14. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the Department of Veterans Affairs health care system. Psychiatr Serv. 2009;60(9):1175-1181.
15. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia. Lancet. 2009;373(9657):31-41.
16. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for the DSM-IV Axis I Disorders-Patient Edition (SCID-I/P): Version 2.0. New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1996.
17. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Klauminzer GW, Charney DS. A clinician rating scale for assessing current and lifetime PTSD: the CAPS-1. Behav Ther. 1990;13:187-188.
18. Cramer JA, Rosenheck R. Enhancing medication compliance for people with serious mental illness. J Nerv Ment Dis. 1999;187(1):53-55. (Pubitemid 29063085)
19. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA; Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345(24):1734-1739.
20. Blake DD, Weathers FW, Nagy LM, et al. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995;8(1):75-90.
21. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. (Pubitemid 9136500)
22. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
23. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS). Br J Psychiatry Suppl. 1989;(7):59-67.
24. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ. 1993;2(3):217-227.
25. Smith AA, Niles BL, King L, King D. Psychometric properties of the Boston Life Satisfaction Inventory among veterans with PTSD. Paper presented at: Annual Meeting of the International Society for Traumatic Stress Studies; December 2001; New Orleans, Louisiana.
26. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence. Br J Addict. 1991;86(9):1119-1127.
27. Sobell LC, Sobell MB, Leo GI, Cancilla A. Reliability of a timeline method. Br J Addict. 1988;83(4):393-402.
28. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676. (Pubitemid 19154942)
29. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
30. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Dept of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch; 1976:534-537.
31. Schnurr PP, Friedman MJ, Lavori PW, Hsieh FY. Design of Department of Veterans Affairs Cooperative Study No. 420. Control Clin Trials. 2001;22 (1):74-88.
32. Weathers FW, Keane TM, Davidson JR. Clinician-administered PTSD scale. Depress Anxiety. 2001;13(3):132-156.
33. Fontana A, Rosenheck R. Effectiveness and cost of the inpatient treatment of posttraumatic stress disorder. Am J Psychiatry. 1997;154(6):758-765. (Pubitemid 27230097)
34. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life. Med Care. 2003;41(5):582-592.
35. Lunney CA, Schnurr PP. Domains of quality of life and symptoms in male veterans treated for posttraumatic stress disorder. J Trauma Stress. 2007;20(6):955-964.
36. Gueorguieva R, Krystal JH. Move over ANOVA. Arch Gen Psychiatry. 2004;61(3):310-317.
37. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
38. Davidson JR. Remission in post-traumatic stress disorder (PTSD). Int Clin Psychopharmacol. 2004;19(2):85-87.
39. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs. Psychopharmacology (Berl). 1996;124(1-2):57-73.
40. Mellman TA, Clark RE, Peacock WJ. Prescribing patterns for patients with posttraumatic stress disorder. Psychiatr Serv. 2003;54(12):1618-1621. (Pubitemid 37486943)
41. Raskind MA, Peskind ER, Hoff DJ, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry. 2007;61(8):928-934. (Pubitemid 46505008)
42. Taylor FB, Lowe K, Thompson C, et al. Daytime prazosin reduces psychological distress to trauma specific cues in civilian trauma posttraumatic stress disorder. Biol Psychiatry. 2006;59(7):577-581. (Pubitemid 43357950)
43. Harpaz-Rotem I, Rosenheck RA. Tracing the flow of knowledge. Arch Gen Psychiatry. 2009;66(4):417-421.
44. Pivac N, Kozarić-Kovacić D. Pharmacotherapy of treatment-resistant combat-related posttraumatic stress disorder with psychotic features. Croat Med J. 2006; 47(3):440-451.
45. Rothbaum BO, Killeen TK, Davidson JR, Brady KT, Connor KM, Heekin MH. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry. 2008;69(4):520-525. (Pubitemid 351792325)
46. Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW. Adjunctive risperidone treatment in post-traumatic stress disorder. Int Clin Psychopharmacol. 2003;18(1):1-8.
47. Hamner MB, Robert S. Emerging roles for atypical antipsychotics in chronic post-traumatic stress disorder. Expert Rev Neurother. 2005;5(2):267-275. (Pubitemid 40445148)